Cited by 1,139Acute Myeloid Leukemia ResearchEpigenetics and DNA MethylationChromatin Remodeling and Cancer

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Ernst, Thomas, Chase, Andrew J, Score, Joannah, Hidalgo-Curtis, Claire E, Bryant, Catherine, Jones, Amy V, Waghorn, Katherine, Zoi, Katerina, Ross, Fiona M, Reiter, Andreas, Hochhaus, Andreas, Drexler, Hans G, Duncombe, Andrew, Cervantes, Francisco, Oscier, David, Boultwood, Jacqueline, Grand, Francis H, Cross, Nicholas C P·2010·Nature Genetics

DOI 10.1038/ng.621

Open this paper in CoChat — free account

Abstract

Abnormalities of chromosome 7q are common in myeloid malignancies, but no specific target genes have yet been identified. Here, we describe the finding of homozygous EZH2 mutations in 9 of 12 individuals with 7q acquired uniparental disomy. Screening of a total of 614 individuals with myeloid disorders revealed 49 monoallelic or biallelic EZH2 mutations in 42 individuals; the mutations were found most commonly in those with myelodysplastic/myeloproliferative neoplasms (27 out of 219 individuals, or 12%) and in those with myelofibrosis (4 out of 30 individuals, or 13%). EZH2 encodes the catalytic subunit of the polycomb repressive complex 2 (PRC2), a highly conserved histone H3 lysine 27 (H3K27) methyltransferase that influences stem cell renewal by epigenetic repression of genes involved in cell fate decisions. EZH2 has oncogenic activity, and its overexpression has previously been causally linked to differentiation blocks in epithelial tumors. Notably, the mutations we identified resulted in premature chain termination or direct abrogation of histone methyltransferase activity, suggesting that EZH2 acts as a tumor suppressor for myeloid malignancies.

Integrity signals

Registry

Crossref · 10.1038/ng.621

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
Detection of large-scale variation in the human genome
Iafrate, A. J., Feuk, L., Rivera, M. N., Listewnik, M. L., Donahoe, P. K., Qi, Y., Scherer, S. W., & Lee, C. (2004) · Nature Genetics · doi:10.1038/ng1416 · Cited by 2,892
The Polycomb group protein EZH2 directly controls DNA methylation
Viré, E., Brenner, C., Deplus, R., Blanchon, L., Fraga, M., Didelot, C., Morey, L., Van Eynde, A., Bernard, D., Vanderwinden, J.-M., et al. (2006) · Nature · doi:10.1038/nature04431 · Cited by 2,204
Mutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
Morin, R. D., Johnson, N. A., Severson, T., Mungall, A. J. J., An, J., Goya, R., Paul, J. E., Boyle, M., Woolcock, B. W., Kuchenbauer, F. C., et al. (2010) · Nature Genetics · doi:10.1038/ng.518 · Cited by 1,719
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596
Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex
Müller, J., Hart, C. M., Francis, N. J., Vargas, M. L., Sengupta, A. K., Wild, B., Miller, E., O’Connor, M. B., Kingston, R. E., & Simon, J. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00976-5 · Cited by 1,553
Drosophila Enhancer of Zeste/ESC Complexes Have a Histone H3 Methyltransferase Activity that Marks Chromosomal Polycomb Sites
Czermin, B., Melfi, R., McCabe, D., Seitz, V., Imhof, A., & Pirrotta, V. (2002) · Cell · doi:10.1016/s0092-8674(02)00975-3 · Cited by 1,536

Flagged first, then by citations

Show all 40 references

Sorted by citations

Items 301–400 of 1,000

Chronic Myelogenous Leukemia, Version 1.2015
O’Brien, S., Radich, J. P., Abboud, C. N., Akhtari, M., Altman, J. K., Berman, E., Curtin, P. T., DeAngelo, D. J., Deininger, M. W., Devine, S. M., et al. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0159 · Cited by 70
Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics
Copeland, R. A., Moyer, M. P., & Richon, V. M. (2012) · Oncogene · doi:10.1038/onc.2012.552 · Cited by 71
SWI/SNF complexes in hematological malignancies: biological implications and therapeutic opportunities
Andrades, Á., Peinado, P., Álvarez-Pérez, J. C., Sanjuán‐Hidalgo, J., García, D. J., Arenas, A. M., Matia‐González, A. M., & Medina, P. P. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01736-8 · Cited by 81
Epigenetics and B-cell lymphoma
Shaknovich, R., & Melnick, A. M. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32834788cf · Cited by 74
Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression
Wu, S., Tang, J., Lin, C., Kuo, Y., Li, L.-Y., Tseng, M., Huang, C., Lai, Y., Lee, F., Liu, M.-C., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23541 · Cited by 71
Toward Individualized Therapy in Acute Myeloid Leukemia
Kadia, T. M., Ravandi, F., Cortes, J. E., & Kantarjian, H. M. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0617 · Cited by 71
Lysine methylation of promoter-bound transcription factors and relevance to cancer
Stark, G. R., Wang, Y., & Lu, T. (2010) · Cell Research · doi:10.1038/cr.2010.174 · Cited by 69
Lack of association ofIDH1, IDH2andDNMT3Amutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents
Dinardo, C. D., Patel, K. P., Garcia‐Manero, G., Luthra, R., Pierce, S. A., Borthakur, G. M., Jabbour, E. J., Kadia, T. M., Pemmaraju, N., Konopleva, M. Y., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.855309 · Cited by 72
Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease
How, J., Zhou, A. W., & Oh, S. T. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716680333 · Cited by 73
Cancer-associated rs6983267 SNP and its accompanying long noncoding RNACCAT2induce myeloid malignancies via unique SNP-specific RNA mutationsPreprint
Shah, M., Ferracin, M., Pileczki, V., Chen, B., Redis, R. S., Fabris, L., Zhang, X., Ivan, C., Shimizu, M., Rodriguez‐Aguayo, C., et al. (2018) · Genome Research · doi:10.1101/gr.225128.117 · Cited by 68
Splicing and cancer: Challenges and opportunities
Coltri, P. P., dos Santos, M. G. P., & Silva, G. K. (2019) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1527 · Cited by 69
A comprehensive review of genetic alterations and molecular targeted therapies for the implementation of personalized medicine in acute myeloid leukemia
Kirtonia, A., Pandya, G., Sethi, G., Pandey, A. K., Das, B. C., & Garg, M. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01944-5 · Cited by 68
Genome Wide Analysis of Acute Myeloid Leukemia Reveal Leukemia Specific Methylome and Subtype Specific Hypomethylation of Repeats
Saied, M. H., Marzec, J., Khalid, S., Smith, P., Down, T. A., Rakyan, V. K., Molloy, G., Raghavan, M., Debernardi, S., & Young, B. D. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033213 · Cited by 68
H3K27 Methylation
Nichol, J. N., Dupéré-Richer, D., Ezponda, T., Licht, J. D., & Miller, W. H. (2016) · Advances in cancer research · doi:10.1016/bs.acr.2016.05.001 · Cited by 75
Genomics of Myeloproliferative Neoplasms
Zoi, K., & Cross, N. C. P. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7968 · Cited by 73
Self-citation
Molecular mechanisms and therapeutic targets in pediatric brain tumors
Liu, K.-W., Pajtler, K. W., Worst, B. C., Pfister, S. M., & Wechsler‐Reya, R. J. (2017) · Science Signaling · doi:10.1126/scisignal.aaf7593 · Cited by 67
Recent progress toward epigenetic therapies: the example of mixed lineage leukemia
Neff, T., & Armstrong, S. A. (2013) · Blood · doi:10.1182/blood-2013-02-474833 · Cited by 68
EZH2 in Myeloid Malignancies
Rinke, J., Chase, A., Cross, N. C. P., Hochhaus, A., & Ernst, T. (2020) · Cells · doi:10.3390/cells9071639 · Cited by 71
Self-citation
Polycomb proteins in hematologic malignancies
Martin-Perez, D., Piris, M. A., & Sanchez-Beato, M. (2010) · Blood · doi:10.1182/blood-2010-05-267096 · Cited by 65
Gene mutations of acute myeloid leukemia in the genome era
Naoe, T., & Kiyoi, H. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1257-4 · Cited by 68
JARID2 Is Involved in Transforming Growth Factor-Beta-Induced Epithelial-Mesenchymal Transition of Lung and Colon Cancer Cell Lines
Tange, S., Oktyabri, D., Terashima, M., Ishimura, A., & Suzuki, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115684 · Cited by 64
EZH2 Mutations Are Related to Low Blast Percentage in Bone Marrow and -7/del(7q) in De Novo Acute Myeloid Leukemia
Wang, X., Dai, H., Wang, Q., Wang, Q., Xu, Y., Wang, Y., Sun, A., Ruan, J., Chen, S., & Wu, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061341 · Cited by 66
Next‐generation sequencing – feasibility and practicality in haematology
Kohlmann, A., Großmann, V., Nadarajah, N., & Haferlach, T. (2013) · British Journal of Haematology · doi:10.1111/bjh.12194 · Cited by 65
The Multiple Facets of PRC2 Alterations in Cancers
Wassef, M. A., & Margueron, R. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.10.012 · Cited by 72
The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER‐positive breast cancers
Bae, W. K., Yoo, K. H., Lee, J. S., Kim, Y., Chung, I., Park, M. H., Yoon, J. H., Furth, P. A., & Hennighausen, L. G. (2014) · Molecular Carcinogenesis · doi:10.1002/mc.22188 · Cited by 66
Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia
Danis, E. P., Yamauchi, T., Echanique, K. A., Zhang, X., Haladyna, J. N., Riedel, S. S., Zhu, N., Xie, H., Orkin, S. H., Armstrong, S. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.064 · Cited by 64
Polycomb complexes in normal and malignant hematopoiesis
Carlo, V. D., Mocavini, I., & Croce, L. D. (2018) · The Journal of Cell Biology · doi:10.1083/jcb.201808028 · Cited by 66
The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
Smedt, E. D., Lui, H., Maes, K., Veirman, K. D., Menu, E., Vanderkerken, K., & Bruyne, E. D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00566 · Cited by 62
Building the Connectivity Map of epigenetics: Chromatin profiling by quantitative targeted mass spectrometry
Creech, A. L., Taylor, J. E., Maier, V., Wu, X., Feeney, C. M., Udeshi, N. D., Peach, S. E., Boehm, J. S., Lee, J. T., Carr, S. A., et al. (2014) · Methods · doi:10.1016/j.ymeth.2014.10.033 · Cited by 62
Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable
Zoi, K., & Cross, N. C. P. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1670-3 · Cited by 62
Self-citation
Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma
Furukawa, Y., & Kikuchi, J. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2048-5 · Cited by 65
World Health Organization Classification, Evaluation, and Genetics of the Myeloproliferative Neoplasm Variants
Vardiman, J. W., & Hyjek, E. M. (2011) · Hematology · doi:10.1182/asheducation-2011.1.250 · Cited by 61
Regulating Methylation at H3K27: A Trick or Treat for Cancer Cell Plasticity
Das, P., & Taube, J. H. (2020) · Cancers · doi:10.3390/cancers12102792 · Cited by 61
Paradoxical role of CBX8 in proliferation and metastasis of colorectal cancer
Tang, J., Wang, G., Zhang, M., Li, F., Sang, Y., Wang, B., Hu, K., Wu, Y., Luo, R., Liao, D., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2502 · Cited by 59
The role of mutations in epigenetic regulators in myeloid malignancies
Woods, B. A., & Levine, R. L. (2014) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 63
Polycomb-group proteins in hematopoietic stem cell regulation and hematopoietic neoplasms
Radulović, V., de Haan, G., & Klauke, K. (2012) · Leukemia · doi:10.1038/leu.2012.368 · Cited by 62
3D genome organization in health and disease: emerging opportunities in cancer translational medicine
Babu, D., & Fullwood, M. J. (2015) · Nucleus · doi:10.1080/19491034.2015.1106676 · Cited by 59
Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2
Christofides, A., Karantanos, T., Bardhan, K., & Boussiotis, V. A. (2016) · Oncotarget · doi:10.18632/oncotarget.12928 · Cited by 61
Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia
Sun, Y., Chen, B.-R., & Deshpande, A. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00041 · Cited by 64
Clinical implications of the SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease progression
Hou, H., Kuo, Y., Tang, J., Chou, W., Yao, M., Lai, Y.-J., Lin, C., Chen, C., Liu, C., Tseng, M., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23611 · Cited by 59
Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis
Skov, V., Larsen, T. S., Thomassen, M., Riley, C. H., Jensen, M. K., Bjerrum, O. W., Kruse, T. A., & Hasselbalch, H. C. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01618.x · Cited by 60
Exploiting epigenetic dependencies in ovarian cancer therapy
Coughlan, A. Y., & Testa, G. (2021) · International Journal of Cancer · doi:10.1002/ijc.33727 · Cited by 58
EZH2-mediated development of therapeutic resistance in cancer
Kaur, P., Shankar, E., & Gupta, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216706 · Cited by 64
Epigenetic alterations in hematopoietic malignancies
Chung, Y. R., Schatoff, E. M., & Abdel-Wahab, O. I. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1181-z · Cited by 59
Genetics of Myeloproliferative Neoplasms
Viny, A. D., & Levine, R. L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000013 · Cited by 60
Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia
Broux, M., Prieto, C., Demeyer, S., Bempt, M. V., Servera, L. A., Lodewijckx, I., Vandepoel, R., Mentens, N., Gielen, O., Jacobs, K., et al. (2019) · Blood · doi:10.1182/blood.2019000015 · Cited by 57
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians
Harrison, C. N., & Vannucchi, A. M. (2012) · Therapeutic Advances in Hematology · doi:10.1177/2040620712459746 · Cited by 57
Is Glioblastoma an Epigenetic Malignancy?
Maleszewska, M., & Kaminska, B. (2013) · Cancers · doi:10.3390/cancers5031120 · Cited by 63
Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma
Wang, Y., Hou, N., Cheng, X., Zhang, J., Tan, X., Zhang, C., Tang, Y., Teng, Y., & Yang, X. Y. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.19108 · Cited by 60
Epigenetics in myelodysplastic syndromes
Heuser, M., Yun, H., & Thol, F. R. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.07.009 · Cited by 61
The DNA methylation landscape of hematological malignancies: an update
Blecua, P., Martinez‐Verbo, L., & Esteller, M. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12744 · Cited by 57
Pharmacological targeting of the cancer epigenome
Mabe, N. W., Perry, J. A., Malone, C. F., & Stegmaier, K. (2024) · Nature Cancer · doi:10.1038/s43018-024-00777-2 · Cited by 61
Integration of Next-Generation Sequencing Into Clinical Practice: Are We There Yet?
Kohlmann, A., Grossmann, V., & Haferlach, T. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.11.008 · Cited by 57
Polycomb group proteins and MYC: the cancer connection
Benetatos, L., Vartholomatos, G., & Hatzimichael, E. C. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1426-x · Cited by 57
Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies
Passamonti, F., Maffioli, M., Caramazza, D., & Cazzola, M. (2011) · Oncotarget · doi:10.18632/oncotarget.281 · Cited by 58
Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis
Eriksson, A., Lennartsson, A., & Lehmann, S. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.009 · Cited by 62
Epigenetic determinants of metastasis
Patel, S. A., & Vanharanta, S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.09.008 · Cited by 58
Polycomb repressive complexes in hematological malignancies
Iwama, A. (2017) · Blood · doi:10.1182/blood-2017-02-739490 · Cited by 55
Genetics of Myelodysplastic Syndromes: New Insights
Graubert, T. A., & Walter, M. J. (2011) · Hematology · doi:10.1182/asheducation-2011.1.543 · Cited by 56
Leveraging epigenetics to enhance the efficacy of immunotherapy
Licht, J. D., & Bennett, R. L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01100-x · Cited by 54
The CUL4B/AKT/β-Catenin Axis Restricts the Accumulation of Myeloid-Derived Suppressor Cells to Prohibit the Establishment of a Tumor-Permissive Microenvironment
Qian, Y., Yuan, J., Hu, H., Yang, Q., Li, J., Zhang, S., Jiang, B., Shao, C., & Gong, Y. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0898 · Cited by 53
Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms
Pérez, C., Pascual, M., Martín-Subero, J. I., Bellosillo, B., Segura, V., Delabesse, É., Álvarez, S., Larráyoz, M. J., Rifón, J., Cigudosa, J. C., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.084160 · Cited by 57
Self-citation
Epigenetic-based therapy: From single- to multi-target approaches
Benedetti, R., Conte, M., Iside, C., & Altucci, L. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.10.016 · Cited by 56
Epigenetic regulation in the pathogenesis of non-melanoma skin cancer
Kashyap, M. P., Sinha, R., Mukhtar, M. S., & Athar, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.11.009 · Cited by 57
EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms
Ueda, T., Sanada, M., Matsui, H., Yamasaki, N., Honda, Z.-I., Shih, L.-Y., Mori, H., Inaba, T., Ogawa, S., & Honda, H. (2012) · Leukemia · doi:10.1038/leu.2012.146 · Cited by 54
Genetic Events That Shape the Cancer Epigenome
Ryan, R. J. H., & Bernstein, B. (2012) · Science · doi:10.1126/science.1223730 · Cited by 55
Mechanisms of DNA Methylation Regulatory Function and Crosstalk with Histone Lysine Methylation
Tibben, B. M., & Rothbart, S. B. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.168394 · Cited by 61
Inherited predisposition to myeloproliferative neoplasms
Jones, A. V., & Cross, N. C. P. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713489144 · Cited by 58
Self-citation
Recurrent genetic defects on chromosome 7q in myeloid neoplasms
Hosono, N., Makishima, H., Jerez, A., Yoshida, K., Przychodzen, B. P., McMahon, S., Shiraishi, Y., Chiba, K., Tanaka, H., Miyano, S., et al. (2014) · Leukemia · doi:10.1038/leu.2014.25 · Cited by 54
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1
Saygin, C., Hirsch, C. M., Przychodzen, B. P., Sekeres, M. A., Hamilton, B. K., Kalaycio, M. E., Carraway, H. E., Gerds, A. T., Mukherjee, S., Nazha, A., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-017-0040-9 · Cited by 51
Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms
McClure, R. F., Ewalt, M. D., Crow, J., Temple‐Smolkin, R., Pullambhatla, M., Sargent, R. L., & Kim, A. S. (2018) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2018.07.002 · Cited by 54
Polycomb Repressive Complex 2 Modulation through the Development of EZH2–EED Interaction Inhibitors and EED Binders
Tomassi, S., Romanelli, A., Zwergel, C., Valente, S., & Mai, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00226 · Cited by 57
DNA methylation as a pathogenic event and as a therapeutic target in AML
Schoofs, T., & Müller‐Tidow, C. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.04.013 · Cited by 56
Myelodysplastic/Myeloproliferative Neoplasms
Cazzola, M., Malcovati, L., & Invernizzi, R. (2011) · Hematology · doi:10.1182/asheducation-2011.1.264 · Cited by 55
Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma
Tiffen, J. C., Wilson, S. P., Gallagher, S. J., Hersey, P., & Filipp, F. V. (2016) · Neoplasia · doi:10.1016/j.neo.2016.01.003 · Cited by 54
Mutations in MPNs: prognostic implications, window to biology, and impact on treatment decisions
Shammo, J. M., & Stein, B. L. (2016) · Hematology · doi:10.1182/asheducation-2016.1.552 · Cited by 57
Uncovering the DNA methylome in chronic lymphocytic leukemia
Cahill, N., & Rosenquist, R. (2013) · Epigenetics · doi:10.4161/epi.23439 · Cited by 52
Robustness of Amplicon Deep Sequencing Underlines Its Utility in Clinical Applications
Grossmann, V., Roller, A., Klein, H., Weißmann, S., Kern, W., Haferlach, C., Dugas, M., Haferlach, T., Schnittger, S., & Kohlmann, A. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.03.003 · Cited by 52
Lethal myelofibrosis induced by Bmi1 -deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes
Oguro, H., Yuan, J., Tanaka, S., Miyagi, S., Mochizuki‐Kashio, M., Ichikawa, H., Yamazaki, S., Koseki, H., Nakauchi, H., & Iwama, A. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20111709 · Cited by 56
Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies
Sashida, G., & Iwama, A. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2124-x · Cited by 55
MPN: The Molecular Drivers of Disease Initiation, Progression and Transformation and their Effect on Treatment
Grabek, J., Straube, J., Bywater, M. J., & Lane, S. (2020) · Cells · doi:10.3390/cells9081901 · Cited by 60
Gene mutations and molecularly targeted therapies in acute myeloid leukemia.
Hatzimichael, E. C., Georgiou, G. K., Benetatos, L., & Briasoulis, E. C. (2013) · Europe PMC (PubMed Central) · Cited by 50
Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
Ott, M., Litzenburger, U. M., Sahm, F., Rauschenbach, K. J., Tudoran, R., Hartmann, C. J., Márquez, V. E., von Deimling, A., Wick, W., & Platten, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047663 · Cited by 55
Myeloproliferative neoplasms: Current molecular biology and genetics
Saeidi, K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.004 · Cited by 53
Monosomy 7 in Pediatric Myelodysplastic Syndromes
Włodarski, M. W., Sahoo, S. S., & Niemeyer, C. M. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.04.007 · Cited by 52
HTLV-1-Mediated Epigenetic Pathway to Adult T-Cell Leukemia–Lymphoma
Yamagishi, M., Fujikawa, D., Watanabe, T., & Uchimaru, K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01686 · Cited by 51
Clinical Implications of the SETBP1 Mutation in Patients With Primary Myelodysplastic Syndrome and its Stability During Disease Progression
Hou, H., Kuo, Y. Y., Tang, J., Chou, W. W., Yao, M., Lai, Y., Lin, C., Chen, C., Liu, C. Y., Lee, M. C., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.06.095 · Cited by 50
Molecular regulators of HOXA9 in acute myeloid leukemia
Aryal, S., Zhang, Y., Wren, S. N., Li, C., & Lu, R. (2021) · FEBS Journal · doi:10.1111/febs.16268 · Cited by 50
−7/7q− syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity
Honda, H., Nagamachi, A., & Inaba, T. (2014) · Oncogene · doi:10.1038/onc.2014.196 · Cited by 50
Laboratory Practice Guidelines for Detecting and Reporting JAK2 and MPL Mutations in Myeloproliferative Neoplasms
Gong, J. Z., Cook, J. R., Greiner, T. C., Hedvat, C. V., Hill, C. E., Lim, M. S., Longtine, J. A., Sabath, D. E., & Wang, Y. L. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.07.002 · Cited by 50
Epigenetic targets and drug discovery
Liu, Y., Liu, K., Su, Q., Xu, C., & Min, J. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.007 · Cited by 51
The role of chromatin modifiers in normal and malignant hematopoiesis
Napierala, J. S., & Dent, S. (2013) · Blood · doi:10.1182/blood-2012-10-451237 · Cited by 55
Drugging Chromatin in Cancer: Recent Advances and Novel Approaches
Cai, S. F., Chen, C.-W. D., & Armstrong, S. A. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.042 · Cited by 50
Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome
Lin, M., Hou, H., Tsai, C., Wu, S., Kuo, Y., Tseng, M., Liu, M.-C., Liu, C., Chou, W., Chen, C., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0476-1 · Cited by 52
Drugging histone methyltransferases in cancer
Richart, L., & Margueron, R. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.009 · Cited by 51
DNA Methyltransferases in Hematologic Malignancies
Li, K. K., Luo, L., Shen, Y., Xu, J., Zhu, C. H., & Chen, S. (2013) · Seminars in Hematology · doi:10.1053/j.seminhematol.2013.01.005 · Cited by 50
Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes
Wu, L., Song, L., Xu, L. P., Chang, C., Xu, F., Wu, D., He, Q., Su, J., Zhou, L., Xiao, C., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-4305-2 · Cited by 50
Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies
Mascarenhas, J. O., Roper, N., Chaurasia, P., & Hoffman, R. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0050-6 · Cited by 51
The biology and clinical impact of genetic lesions in myeloid malignancies
Lindsley, R. C., & Ebert, B. L. (2013) · Blood · doi:10.1182/blood-2013-06-460295 · Cited by 50
Genetic profiling in acute myeloid leukaemia ─ where are we and what is its role in patient management
Ofran, Y., & Rowe, J. M. (2012) · British Journal of Haematology · doi:10.1111/bjh.12135 · Cited by 51

Authors: Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., Hochhaus, A., Drexler, H. G., Duncombe, A., Cervantes, F., Oscier, D., Boultwood, J., Grand, F. H., & Cross, N. C. P.
Affiliations: University of Southampton (GB)
Wessex Regional Genetics Laboratory (GB)
Academy of Athens (GR)
Heidelberg University (DE)
Jena University Hospital (DE)
Leibniz Institute DSMZ – German Collection of Microorganisms and Cell Cultures (DE)
Southampton General Hospital (GB)
Hospital Clínic de Barcelona (ES)
Royal Bournemouth Hospital (GB)
John Radcliffe Hospital (GB)
Corresponding author: Cross, Nicholas C P
ORCID: Ernst, Thomas
Chase, Andrew J
Jones, Amy V
Reiter, Andreas
Hochhaus, Andreas
Drexler, Hans G
Duncombe, Andrew
Cervantes, Francisco
Oscier, David
Boultwood, Jacqueline
Cross, Nicholas C P
Venue: Nature Genetics
Publisher: Springer Science and Business Media LLC
Published: 2010-07-04
Volume: 42
Issue: 8
Pages: 722-726
ISSN: 1061-4036 (ISSN-L)
1546-1718
DOI: 10.1038/ng.621
OpenAlex: W1963736125
Cited by: 1,139
References: 40
Citations by year: 2026: 12 · 2025: 32 · 2024: 25 · 2023: 42 · 2022: 33 · 2021: 64 · 2020: 61 · 2019: 52 · 2018: 55 · 2017: 71 · 2016: 113 · 2015: 94 · 2014: 91 · 2013: 132 · 2012: 132
FWCI: 79.07
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Genetics (publishedVersion)
PubMed (publishedVersion)
ePrints Soton (University of Southampton) (submittedVersion)
Topics: Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: EZH2, histone methyltransferase, somatic mutations, myeloid disorders, myelodysplastic/myeloproliferative neoplasms, myelofibrosis, chromosome 7q, uniparental disomy, polycomb repressive complex 2, H3K27 methylation, tumor suppressor, epigenetic repression
MeSH terms: Enhancer of Zeste Homolog 2 Protein, Histone Methyltransferases, Cell Differentiation, DNA-Binding Proteins, Female, Genes, Regulator, Histones, Humans, Lysine, Male, Histone-Lysine N-Methyltransferase, Proteins, Transcription Factors, Genes, Tumor Suppressor, Polycomb Repressive Complex 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks